DaVita beat Q3 estimates but a $62M China charge sent shares lower
DaVita reported Q3 2026 adjusted EPS of $3.82, beating estimates, but shares fell due to a $62M China-related impairment charge. Patient care costs rose to $280.22. The company raised its 2026 EPS guidance to $14.30 and repurchased $111M in shares.
How this was made
The 30-second read
Why it matters
The key trading issue is whether the China charge signals deeper international underperformance and whether cost inflation and per-treatment economics will persist into 2026.
Market read
Despite an EPS beat and higher adjusted EPS guidance floor, the $62M China impairment and international operating loss drove the stock lower, with additional pressure from rising patient care costs and weaker free cash flow.
What to watch
Free cash flow dropped 59% year over year, so traders may be underweighting liquidity and working-capital/capex dynamics versus the headline EPS beat.
Background
DaVita’s Q3 print included an impairment tied to its China business, alongside cost pressure in patient care per treatment.
Ticker impact
DaVita reported Q3 adjusted EPS of $3.82 but shares fell after a $62M non-cash China goodwill and asset impairment charge.
Likely downside bias as investors focus on the China charge, international margin pressure, and free-cash-flow deterioration.
The article attributes the stock drop to the $62M China impairment and notes international operating loss plus higher patient care costs, even as guidance was modestly raised and buybacks continued.
Market effects
Highlights ongoing earnings quality risk for dialysis operators tied to international operations and cost inflation in patient care supplies.
US-listed healthcare names may see read-across selling if investors generalize impairment and margin compression risk.
China-specific impairment underscores geopolitical and operational risk for multinational healthcare providers.
Counterpoint
The raised 2026 adjusted EPS guidance floor and continued buybacks could support longer-term per-share earnings power, offsetting the non-cash nature of the impairment.
Key entities
- companyDaVita
US dialysis provider reporting Q3 adjusted EPS beat, China impairment charge, and updated 2026 guidance floor.
